Jieyang Lu
Sir Run Run Shaw Hospital
Hangzhou, China
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Oncometabolite L-2-hydroxyglurate directly induces vasculogenic mimicry through PHLDB2 in renal cell carcinoma.
Journal: International journal of cancer
Published: May 26, 2020
Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells.
Journal: Aging
Published: February 06, 2020
Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Journal: Cell death & disease
Published: December 20, 2019
Targeting the TR4 nuclear receptor with antagonist bexarotene can suppress the proopiomelanocortin signalling in AtT-20 cells.
Journal: Journal of cellular and molecular medicine
Published: August 26, 2019
Development and verification of a nomogram for prediction of recurrence-free survival in clear cell renal cell carcinoma.
Journal: Journal of cellular and molecular medicine
Published: April 26, 2019
Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.
Journal: International journal of cancer
Published: July 23, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026